Moreover, knockdown of NCAPG can resensitize HER2-resistant breast cancer cells to trastuzumab, indicating that NCAPG has the potential to become a predictive biomarker and target for therapeutic intervention for trastuzumab resistance in HER2-resistant breast cancer cells (16). Here, ERBB2 is linked to breast cancer.